{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:36:12Z","timestamp":1792082172014,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1038\/sj.ijo.0801889","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:34:59Z","timestamp":1031250899000},"page":"262-273","source":"Crossref","is-referenced-by-count":228,"title":["Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials"],"prefix":"10.1038","volume":"26","author":[{"given":"CK","family":"Haddock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WSC","family":"Poston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PL","family":"Dill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JP","family":"Foreyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ericsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,2,15]]},"reference":[{"key":"BF0801889_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2125.1995.tb05779.x","volume":"40","author":"GK Lijesen","year":"1995","unstructured":"Lijesen GK, Theeuwen I, Assendelft WF, Van Der Wal G . The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis Br J Clin Pharmac 1995 40: 237\u2013243.","journal-title":"Br J Clin Pharmac"},{"issue":"Suppl","key":"BF0801889_CR2","first-page":"S38","volume":"22","author":"GaalLF Van","year":"1998","unstructured":"Van Gaal LF, Wauters MA, Peiffer FW, De Leeuw IH . Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal\/visceral fat reduction? Int J Obes Relat Metab Disord 1998 22(Suppl): S38\u2013S40.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BF0801889_CR3","doi-asserted-by":"publisher","first-page":"203S","DOI":"10.1093\/ajcn\/55.1.203s","volume":"55","author":"FL Greenway","year":"1992","unstructured":"Greenway FL . Clinical studies with phenylpropanolamine: a meta-analysis Am J Clin Nutr 1992 55: 203S\u2013205S.","journal-title":"Am J Clin Nutr"},{"key":"BF0801889_CR4","volume-title":"Obesity in perspective, DHEW publication no. (NIH) 75\u2013708.","author":"BA Scoville","year":"1973","unstructured":"Scoville BA . Review of amphetamine like drugs by the Federal Drug Administration: clinical data and value judgments. In: G Bray (ed). Obesity in perspective, DHEW publication no. (NIH) 75\u2013708. US Government Printing Office: Washington, DC 1973."},{"key":"BF0801889_CR5","first-page":"53","volume-title":"Phenylpropanolamine: risks, benefits, and controversies","author":"M Weintraub","year":"1985","unstructured":"Weintraub M . Phenylpropanolamine as an anorexiant agent weight control: a review of published and unpublished studies. In: JD Morgan, DV Kagan, JS Brody (eds). Phenylpropanolamine: risks, benefits, and controversies Praeger: New York 1985 53\u201379."},{"key":"BF0801889_CR6","unstructured":"Committee on Nutrition, Massachusetts Medical Society . Obesity treatment using drug therapy. White paper The Massachusetts Medical Society: Waltham, MA 1998."},{"key":"BF0801889_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/ajcn\/60.5.647","volume":"60","author":"DJ Goldstein","year":"1994","unstructured":"Goldstein DJ, Potvin JH . Long-term weight loss: the effect of pharmacological agents Am J Clin Nutr 1994 60: 647\u2013657.","journal-title":"Am J Clin Nutr"},{"key":"BF0801889_CR8","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1001\/jama.1996.03540230057036","volume":"276","author":"TaskForceonthePreventionandTreatmentofObesity National","year":"1996","unstructured":"National Task Force on the Prevention and Treatment of Obesity . Long-term pharmacotherapy in the management of obesity JAMA 1996 276: 1907\u20131915.","journal-title":"JAMA"},{"key":"BF0801889_CR9","unstructured":"Dietary Supplement Health and Education Act of 1994 (DSHEA). Public Law 103\u2013417: 103rd Congress, 2nd Session Senate, Report 103\u2013410 Washington, DC 1\u201349."},{"key":"BF0801889_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","volume":"106","author":"M Apfelbaum","year":"1999","unstructured":"Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E . Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine Am J Med 1999 106: 179\u2013184.","journal-title":"Am J Med"},{"key":"BF0801889_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/j.1550-8528.1995.tb00189.x","volume":"3","author":"TA Wadden","year":"1995","unstructured":"Wadden TA, Bartlett SJ, Foster GD, Greenstein RA, Wingate BJ, Stunkard AJ, Letizia KA . Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial Obes Res 1995 3: 549\u2013557.","journal-title":"Obes Res"},{"key":"BF0801889_CR12","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","volume":"356","author":"WPT James","year":"2000","unstructured":"James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WHM, Van Gaal LF . Effects of sibutramine on weight maintenance after weight loss: a randomized trial Lancet 2000 356: 2119\u20132125.","journal-title":"Lancet"},{"key":"BF0801889_CR13","first-page":"231","volume-title":"The handbook of research synthesis","author":"R Rosenthal","year":"1994","unstructured":"Rosenthal R . Parametric measures of effect size. In: H Cooper, LV Hedges (eds). The handbook of research synthesis Russell Sage: New York 1994 231\u2013244."},{"key":"BF0801889_CR14","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1037\/0003-066X.48.12.1181","volume":"48","author":"MW Lipsey","year":"1993","unstructured":"Lipsey MW, Wilson DB . The efficacy of psychological, educational, and behavioral treatment: confirmation from meta-analysis Am Psychol 1993 48: 1181\u20131209.","journal-title":"Am Psychol"},{"key":"BF0801889_CR15","first-page":"261","volume-title":"The handbook of research synthesis","author":"WR Shadish,","year":"1994","unstructured":"Shadish, WR, Haddock, CK . Combining estimates of effect size. In: H Cooper, LV Hedges (eds). The handbook of research synthesis Russell Sage: New York 1994 261\u2013281."},{"key":"BF0801889_CR16","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1037\/0033-2909.92.2.490","volume":"92","author":"LV Hedges","year":"1982","unstructured":"Hedges LV . Estimation of effect size from a series of independent experiments Psychol Bull 1982 92: 490\u2013499.","journal-title":"Psychol Bull"},{"key":"BF0801889_CR17","volume-title":"Statistical methods for meta-analysis","author":"LV Hedges","year":"1985","unstructured":"Hedges LV, Olkin I . Statistical methods for meta-analysis Academic Press: San Diego, CA 1985."},{"key":"BF0801889_CR18","unstructured":"Cooper H, Hedges LV . The handbook of research synthesis (Part VI) Russell Sage: New York 1994."},{"key":"BF0801889_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J . A power primer Psychol Bull 1992 112: 155\u2013159.","journal-title":"Psychol Bull"},{"key":"BF0801889_CR20","unstructured":"National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity: the evidence report US Government Press: Washington DC 1998."},{"key":"BF0801889_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1037\/0033-2909.97.2.307","volume":"97","author":"DJ Ozer","year":"1985","unstructured":"Ozer DJ . Correlation and the coefficient of determination Psychol Bull 1985 97: 307\u2013315.","journal-title":"Psychol Bull"},{"key":"BF0801889_CR22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/35007508","volume":"404","author":"PG Kopelman","year":"2000","unstructured":"Kopelman PG . Obesity as a medical problem Nature 2000 404: 635\u2013643.","journal-title":"Nature"},{"key":"BF0801889_CR23","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1056\/NEJM200012213432501","volume":"343","author":"WN Kernan","year":"2000","unstructured":"Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Mogenstern LB, Wilterdink JL, Horwitz RI . Phenylpronanolamine and the risk of hemorrhagic stroke New Engl J Med 2000 343: 1826\u20131832.","journal-title":"New Engl J Med"},{"key":"BF0801889_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2165\/00002018-199920020-00003","volume":"20","author":"J Kolanowski","year":"1999","unstructured":"Kolanowski J . A risk\u2013benefit assessment of anti-obesity drugs Drug Safety 1999 20: 119\u2013131.","journal-title":"Drug Safety"},{"key":"BF0801889_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/sj.ijo.0800795","volume":"23","author":"AJ Scheen","year":"1999","unstructured":"Scheen AJ, Lefebvre PJ . Pharmacological treatment of obesity: present status Int J Obes Relat Metab Disord 1999 23: 47\u201353.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BF0801889_CR26","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1056\/NEJM200012213432502","volume":"343","author":"CA Haller","year":"2000","unstructured":"Haller CA, Benowitz NL . Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids New Engl J Med 2000 343: 1833\u20131838.","journal-title":"New Engl J Med"},{"key":"BF0801889_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/j.1550-8528.1999.tb00709.x","volume":"7","author":"FL Greenway","year":"1999","unstructured":"Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR . Pharmaceutical cost savings of treating obesity with weight loss medications Obes Res 1999 7: 523\u2013531.","journal-title":"Obes Res"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/0801889.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/0801889","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/0801889.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T07:21:50Z","timestamp":1684221710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/0801889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["BF0801889"],"URL":"https:\/\/doi.org\/10.1038\/sj.ijo.0801889","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}